Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (311-320 of 320) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 320 results.
Lancet (London, England)|June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialMichael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerSherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
Pageof 32

Showing results (311-320 of 320) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 320 results.
Lancet (London, England)|June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialMichael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerSherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
Pageof 32